[Effect of combined use of radiation and twice intratumor administration of OK-432 at one week intervals against a murine fibrosarcoma (NFSA)].
Effect of combination use of radiation and multiple administration of OK-432 was studied using a radio-resistant and weakly immunogenic murine fibrosarcoma (NFSa) originated spontaneously in a C3H female mouse. Mice implanted the tumor in the leg were locally irradiated with 40 Gy of gamma rays and locally administered total 8 KE of OK-432. The first group was given 1 KE daily for 8 days, 2 KE every other day in the 2nd group, 4 KE at 1 week interval in the 3rd group and 8 KE immediately after irradiation in the 4th group. The tumor volume at day 19 after irradiation was compared. The tumor growth inhibitory effect was observed in the 3rd group (p less than 0.01) and 4th group (p less than 0.05) compared to the group given radiation alone. This effect was seen at even more smaller dose of OK-432 as 0.5 KE by 2 times administration at 1 week interval. The effect of route of OK-432 administration was studied comparing the tumor volume at day 22. OK-432 was given 2 times at 1 week interval. A significant difference was seen in the group given OK-432 locally compared to the control group given radiation alone (p less than 0.001). There were no significant differences between the groups given OK-432 by the routes of i.p., s.c. i.v. and the control group. TCD50 value was examined giving OK-432 4 KE on the day and 2 KE on day 7 after irradiation. TCD50 value in the group treated with irradiation alone was 83.5 (79.6-87.4) Gy and the group given combination therapy with OK-432 was 60.7 (55.9-65.4) Gy. Two times OK-432 administration at 1 week interval appears to potentiate the radiation response by about 23 Gy.
Mukai
M
M
Hospital Division, National Institute of Radiological Sciences.
Ando
K
K
Koike
S
S
D000818:Animals; D001688:Biological Products / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005354:Fibrosarcoma / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D010844:Picibanil / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D012513:Sarcoma, Experimental / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
D001688:Biological Products; D010844:Picibanil